High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment ...

Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until ...

Biochemical recurrence is when your PSA level starts to rise after finishing prostate cancer treatment, and it may sometimes indicate metastatic disease. Biochemical recurrence is a term for when your ...

Men with a detectable PSA after radical prostatectomy (RP) are often offered salvage therapy while those with an undetectable PSA are monitored. We aim to better characterize the natural history of ...

Prostate-specific antigen (PSA) recurrence after radical prostatectomy signifies increased risk of metastasis and death from prostate cancer. Traditional clinical metrics may not accurately capture ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

Share on Pinterest UCLA researchers recently found that PSA levels after prostate cancer treatment may not be the best indicator of survival. andresr/Getty Images A new study from UCLA researchers ...

Adding apalutamide to androgen deprivation therapy prolonged prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer in the phase 3 PRESTO trial.

In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with 18 F-DCFPyL PSMA PET/CT has been shown to considerably improve detection of active disease as ...

Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? It is also noteworthy that patients can ...

Results from a surrogacy analysis of the NRG-RTOG 9601 trial indicated that biochemical failure was not an adequate surrogate endpoint for overall survival for patients with recurrent prostate cancer ...